Found 698 clinical trials
Safety Pharmacokinetics and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
ul>
Secondary Objectives:
<ul>- 0 views
- 19 Feb, 2024
- 2 locations
Cervical Ripening Balloons for Same-Day Cervical Prep (CRB)
Participants will:
<ul>- 0 views
- 12 May, 2025
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive
<ul>- 0 views
- 19 Feb, 2024
Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19
Objectives :
Primary objective:
To describe the lung ultrasound lesions in pregnant women in case of suspected or confirmed COVID-19
Secondary objectives:
<ul>- 0 views
- 19 Feb, 2024
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
ul>
The total number of planned study visits for each participant will be 6.
- 0 views
- 14 May, 2025
A Multinational Randomized Double-blind Placebo-controlled Study to Assess the Efficacy Pharmacodynamics Pharmacokinetics and Safety of Venglustat in Late-onset GM2
Primary Objectives:
Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period
Secondary population (participants with juvenile/adolescent late-onset GM2 gangliosidosis, GM1 gangliosidosis, saposin C deficiency, sialidosis type 1 or …
- 0 views
- 19 Feb, 2024
- 2 locations
Multicenter Perspective Study: Clinical Evaluation of the Persona MC With Preservation or Sacrifice of the PCL
Primary endpoint
-Evaluation of the survival of the implant after 5 years of follow-up
Secondary endpoints
<ul>- 0 views
- 19 Feb, 2024
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC (PROPHET)
Researchers will use ctDNA dynamics to guide the cycles of induction treatment to see if some patients can avoid excessive cycles of treatment.--UATul>
- 0 views
- 19 May, 2025
Intratumoral Tilsotolimod a TLR-9 Agonist Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
The trial will be divided into two parts:
PART A:
the first part will assess the safety of two regimen and will recruit patients with all types of injectable solid malignancies
PART B:
the second part will include 3 expansion cohorts of …
- 0 views
- 19 Feb, 2024